Boehringer Ingelheim launches additional heart failure indication for Jardiance in India
Empagliflozin - the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death, in people with type-II…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.